Sanofi-Aventis
3Q Revenues: $9.9 billion (-2%)
3Q Earnings: $1.9 billion (-27%)
YTD Revenues: $29.6 billion (-3%)
YTD Earnings: $5.3 billion (-18%)
Comments: Pharmaceutical sales in the quarter were up 5% to $8.5 billion, driven by the company's top 15 products. Lovenox sales were $917.5 million (+9%). Plavix sales were $910.3 million (+6%). Lantus sales were $884.3 million (+29%). Taxotere sales were up 17% to $261.5 million. Aprovel sales were up 15% to $430.6 million. Copaxone sales were $144.5 million (+19%). In the U.S., sales of Ambien CR and Ambien IR totaled $177 million and $28 million respectively. Vaccines revenue was $1.4 billion in the quarter (+9%). Flu vaccines were up 10% at $540.4 million. Polio/Pertussis/Hib Vaccines were up 43% to $280.3 million. R&D expenses were flat at $1.6 billion in the quarter (or +4.5% after excluding the effect of exchange rates). In the quarter, the company completed the acquisitions of Acambis (vaccines) and Symbion (nutraceuticals/OTC, Australia). 3Q and YTD results include the unfavorable effect of exchange rates.
Magazine
